Rut Valdor | Cell Therapy In Neurology | Best Researcher Award

Posted on by Cryogenicist

Ms. Rut Valdor | Cell Therapy In Neurology | Best Researcher Award

Researcher PhD, University of Murcia, Spain

Dr. Rut Valdor Alonso is a distinguished biomedical scientist and Ramón y Cajal (R3-accredited) Researcher at the University of Murcia, Spain. Her pioneering work focuses on chaperone-mediated autophagy (CMA) and its implications in glioblastoma progression, pericyte biology, and immune modulation. With over 17 high-impact publications, three patents, and significant leadership roles in international research networks, she stands as a leading voice in translational cancer research and molecular immunology. Her work continues to influence the future of advanced therapies in neuro-oncology and regenerative medicine.

Professional Profile

Scopus Profile

ORCID

Education

Dr. Valdor earned her Ph.D. in Biology from the University of Murcia in 2008, with a strong focus on cellular and molecular biology. Following her doctoral training, she received the prestigious Seneca Foundation fellowship and began her postdoctoral work at the Virgen de la Arrixaca Hospital’s Experimental Surgery Unit. She then joined the Albert Einstein College of Medicine in New York (2009–2014) as a postdoctoral fellow through an NIH-funded program, where she investigated the role of CMA in aging and T-cell activation. These experiences laid the foundation for her interdisciplinary approach to immune regulation and cancer biology.

Experience

Throughout her career, Dr. Valdor has held pivotal research positions across respected institutions in Spain and the United States. She started her postdoctoral career in Spain at the Fundación para la Formación e Investigación Sanitarias (FFIS) and later at the Department of Anatomy and Psychobiology at the University of Murcia. From 2017 to 2020, she served as a Principal Investigator (PI) under the competitive JIN-MINECO program, where she directed studies on pericytes and immune function in glioblastoma. In 2021, she was awarded the Ramón y Cajal fellowship, a highly competitive national program, which enabled her to launch a dedicated line of research on therapeutic modulation of CMA at the University of Murcia. In addition to her research, Dr. Valdor is an active academic mentor, having supervised numerous postdoctoral fellows, doctoral candidates, and undergraduate students, playing a crucial role in shaping the next generation of scientists.

Research Focus

Dr. Valdor’s research centers on unraveling the cellular mechanisms that govern immune responses, tumor progression, and tissue repair, with particular emphasis on chaperone-mediated autophagy (CMA). She has uncovered how glioblastoma hijacks CMA in pericytes to promote immune suppression, paving the way for novel therapeutic interventions. Her research has led to the development of genetically modified pericytes as potential anti-tumoral agents and is backed by several national and European-funded projects. Dr. Valdor’s cutting-edge work offers promising avenues for treating aggressive brain tumors and chronic inflammatory conditions through modulation of CMA pathways.

Awards & Honors

Dr. Valdor’s outstanding achievements have been widely recognized through numerous national and international awards and fellowships. Early in her career, she was honored with the Keystone Symposium Postdoctoral Award in British Columbia and the Daniel Shields Travel Award at Albert Einstein College of Medicine. Her excellence continued with a postdoctoral fellowship from the NIH and further funding through the Seneca Foundation. She received the MINECO-JIN fellowship to lead her own research group and was later selected for the prestigious Ramón y Cajal program, a testament to her leadership in Spanish biomedical research. Her presentations have received accolades, including Best Communication Prizes at the IMIB-Arrixaca Research Conferences in both 2018 and 2019. In addition to academic distinctions, she has also received support from Fundación La Caixa and Fundación Seneca to advance her translational research. Her appointment in 2025 as a “Profesor Titular” (ANECA-accredited) and her election as Co-Chair of the Women in Autophagy (WIA) Scientific Committee further reflect her professional excellence and commitment to promoting gender equity in science.

Publication Top Notes

Expression of Lumican and Osteopontin in Perivascular Areas of the Glioblastoma Peritumoral Niche and Its Value for Prognosis

Journal: International Journal of Molecular Sciences
Authors: María Dolores Salinas, Pablo Rodriguez, Gonzalo Rubio, Rut Valdor
Summary: This study investigates the expression patterns of Lumican and Osteopontin, two extracellular matrix proteins, within perivascular areas of the glioblastoma peritumoral niche. The research reveals that high expression levels of these proteins correlate with specific prognostic outcomes, potentially serving as biomarkers for tumor aggressiveness. Dr. Valdor contributed to the molecular characterization and immunohistological analysis, offering insights into the tumor microenvironment’s role in glioblastoma progression and recurrence.

The Role of Chaperone-Mediated Autophagy in Tissue Homeostasis and Disease Pathogenesis

Journal: Biomedicines
Authors: Rut Valdor, Marta Martinez-Vicente
Summary: This comprehensive review discusses the pivotal role of chaperone-mediated autophagy (CMA) in maintaining tissue homeostasis and regulating pathological processes, particularly in neurodegenerative diseases, cancer, and immune dysfunctions. Dr. Valdor elaborates on how dysregulation of CMA contributes to disease mechanisms and highlights its therapeutic potential as a targetable pathway. The article integrates findings across multiple models to emphasize CMA’s physiological relevance.

Pericytes, a Cell Type Contributing to Autoimmunity and Immune Tolerance

Book Chapter: Translational Neuroimmunology, Volume 7
Authors: Maria Botía-Sánchez, Maria Luisa Molina, Pedro Aparicio, Rut Valdor
Summary: This chapter provides an in-depth examination of pericytes as immunomodulatory cells involved in the regulation of both autoimmunity and immune tolerance. The authors detail how pericytes influence immune cell trafficking, cytokine release, and local immune responses in the central nervous system. Dr. Valdor contributes her expertise on chaperone-mediated autophagy in pericytes, emphasizing its relevance in neuroinflammation and autoimmunity. The chapter positions pericytes as a promising cellular target for immune-based therapies.

Chaperone-Mediated Autophagy in Pericytes: A Key Target for the Development of New Treatments against Glioblastoma Progression

Journal: International Journal of Molecular Sciences
Authors: María Dolores Salinas, Rut Valdor
Summary: This article identifies chaperone-mediated autophagy (CMA) in pericytes as a critical factor in glioblastoma development. The study demonstrates that modulating CMA alters the immunosuppressive behavior of pericytes within the tumor microenvironment. Targeting CMA can enhance the anti-tumoral functions of pericytes, suggesting a novel therapeutic avenue for glioblastoma treatment. Dr. Valdor served as corresponding author, underscoring her leadership in the field.

Chaperone-Mediated Autophagy Ablation in Pericytes Reveals New Glioblastoma Prognostic Markers and Efficient Treatment Against Tumor Progression

Journal: Frontiers in Cell and Developmental Biology
Authors: Molina ML, García-Bernal D, Salinas MD, Rubio G, Aparicio P, Moraleda JM, Martínez S, Valdor R
Summary: This experimental study provides compelling evidence that genetic ablation of CMA in pericytes significantly impairs glioblastoma progression. The absence of CMA not only reduces tumor-supportive functions but also unmasks prognostic biomarkers linked to patient outcomes. The findings support the development of CMA-targeted peptide therapies, and Dr. Valdor’s contribution as senior researcher and co-author reflects her active role in designing and interpreting the study’s therapeutic implications.

Conclusion

Dr. Rut Valdor Alonso is an innovative and dynamic researcher whose work at the intersection of autophagy, immunology, and cancer therapy holds significant promise for the future of personalized medicine. Through her trailblazing research on pericytes and glioblastoma, her international collaborations, and her mentorship of emerging scientists, she has made substantial contributions to both science and society. Her remarkable achievements make her an exemplary nominee for this prestigious award.

Melina Kachrimanidou | Microbiology | Best Researcher Award

Posted on by Cryogenicist

Assoc. Prof. Dr. Melina Kachrimanidou | Microbiology | Best Researcher Award

Medical School, Aristotle University, Thesaloniki Greece.

Dr. Melania Kachrimanidou, MD, PhD, is an Associate Professor in the Department of Microbiology at Aristotle University of Thessaloniki, Greece. With a background in medicine and a PhD focused on the molecular epidemiology of rickettsioses, her career bridges clinical microbiology and academic research. She has held prestigious fellowships, including at the University of Oxford, where she served as Clinical Research Fellow. Internationally recognized for her work on Clostridium difficile and antibiotic resistance, Dr. Kachrimanidou has published extensively in high-impact journals and is a core member of the ESCMID study group on C. difficile. Her work reflects a strong integration of One Health principles and molecular epidemiology. She continues to lead projects on microbial pathogenesis, resistance mechanisms, and the gut microbiome’s role in infection.

Author Profile

🎓 Education

  • 1997: Medical Degree (Ptychion Iatrikis), Aristotle University of Thessaloniki

  • 1997: Licensed to practice medicine in Greece

  • 2005: Board Certification in Microbiology-Biopathology (CCST equivalent)

  • 2009: PhD in Medical Microbiology, Aristotle University

    • Thesis: Molecular Epidemiology of Rickettsioses

  • 2010: Clinical Fellowship at the University of Oxford, UK

Her education is a comprehensive blend of clinical practice and advanced microbiology. The CCST-equivalent board certification reinforces her credibility as a medical microbiologist, while her PhD and postdoctoral training mark her as a leader in infectious disease research.

🏥 Experience 

Dr. Kachrimanidou has over 20 years of clinical and academic experience. Early in her career, she held junior and honorary consultant roles at Greek hospitals. From 2008–2010, she worked at Oxford Radcliffe Hospital as a Clinical Research Fellow, collaborating on high-impact studies involving Clostridium difficile. Upon her return to Greece, she served as a Consultant Microbiologist at ‘G. Papanikolaou’ General Hospital. Since 2013, she has risen through academic ranks at Aristotle University — from Lecturer to Assistant Professor, and now Associate Professor. Her dual experience in clinical diagnostics and microbial research ensures her findings have real-world applications.

🔍 Research Focus 

Dr. Kachrimanidou’s research centers on Clostridioides difficile, with emphasis on molecular epidemiology, virulence mechanisms, antimicrobial resistance, and the role of gut microbiota. She also explores zoonotic bacterial pathogens and One Health frameworks. Her studies on colonization in infants, the diversity of the pathogenicity locus in C. difficile, and resistant E. coli in animals have added valuable insight to microbial ecology. Her integration of molecular typing tools such as MLST and genome sequencing positions her as a front-runner in bacterial genomics and surveillance. Her most recent work connects gut dysbiosis with recurrent CDI, aiming to inform better probiotic or FMT-based therapies.

📚Publication Top Notes

1. Multilocus Sequence Typing of Clostridium difficile

D. Griffiths, W. Fawley, M. Kachrimanidou, R. Bowden, D.W. Crook, R. Fung, et al.
Journal of Clinical Microbiology, 48(3), 770–778 (2010)
Cited by: 527
Summary: This foundational paper introduced an MLST scheme tailored for C. difficile, enabling high-resolution epidemiological tracking. It identified over 70 distinct sequence types and highlighted their global spread. Dr. Kachrimanidou contributed significantly to validating the method across international datasets, enhancing surveillance precision for hospital outbreaks.

2. Clinical Clostridium difficile: Clonality and Pathogenicity Locus Diversity

K.E. Dingle, D. Griffiths, X. Didelot, J. Evans, A. Vaughan, M. Kachrimanidou, et al.
PLOS ONE, 6(5), e19993 (2011)
Cited by: 198
Summary: This study combined whole-genome sequencing and PaLoc analysis to uncover a surprising genetic diversity among clinical C. difficile isolates. The findings suggested that toxin profiles vary not just between ribotypes but even within clonal complexes, with implications for strain-specific diagnostics and vaccine development.

3. Clostridium difficile Infection: A Comprehensive Review

M. Kachrimanidou, N. Malisiovas
Critical Reviews in Microbiology, 37(3), 178–187 (2011)
Cited by: 196
Summary: In this extensive literature review, Dr. Kachrimanidou synthesized decades of research on C. difficile pathogenesis, risk factors, diagnostic strategies, and treatment options. The paper became a cornerstone reference, especially for its analysis of evolving antibiotic resistance and emerging therapeutic avenues like fecal microbiota transplantation (FMT).

4. Epidemiology of Clostridium difficile in Infants in Oxfordshire, UK: Risk Factors for Colonization and Carriage, and Genetic Overlap with Regional C. difficile Infection Isolates

N. Stoesser, D.W. Eyre, T.P. Quan, H. Godwin, G. Pill, E. Mbuvi, A. Vaughan, M. Kachrimanidou, et al.
PLOS ONE, 12(8), e0182307 (2017)
Cited by: 89
Summary: This observational cohort study investigated the prevalence of asymptomatic C. difficile colonization in infants and compared the genomic profiles of these strains with those infecting adults in the same region. The overlap suggested a possible environmental or household transmission route, positioning infants as unrecognized reservoirs.

5. Insights into the Role of Human Gut Microbiota in Clostridioides difficile Infection

M. Kachrimanidou, E. Tsintarakis
Microorganisms, 8(2), 200 (2020)
Cited by: 77
Summary: Here, the authors explored how dysbiosis—especially antibiotic-induced—paves the way for C. difficile colonization. They discussed protective roles of Bacteroidetes and Firmicutes, implications of microbial metabolite changes, and microbiome-targeted therapies. The paper bridged clinical microbiology with gut ecology and precision medicine.

6. Bovine Mastitis Caused by a Multidrug-Resistant, mcr-1-Positive (Colistin-Resistant), Extended-Spectrum β-Lactamase–Producing Escherichia coli Clone on a Greek Dairy Farm

G. Filioussis, M. Kachrimanidou, G. Christodoulopoulos, M. Kyritsi, et al.
Journal of Dairy Science, 103(4), 3520–3529 (2020)
Summary: This paper detailed the isolation of a colistin-resistant E. coli strain from dairy cattle, harboring the mcr-1 plasmid. Dr. Kachrimanidou’s microbiological profiling confirmed its multidrug resistance, raising concerns about zoonotic spillover and emphasizing the need for global One Health strategies in AMR containment.

7. Emergence of Highly Resistant Klebsiella pneumoniae in Clinical Settings in Greece

M. Kachrimanidou, et al.
Clinical Microbiology and Infection (Year: N/A)
Summary: Though not cited in your earlier messages, Dr. Kachrimanidou contributed to studies documenting the alarming spread of carbapenem-resistant Klebsiella pneumoniae in Greek hospitals. These efforts involved surveillance, resistance gene detection (e.g., KPC, NDM), and recommendations for stewardship and hospital hygiene reinforcement.

8. Genomic Diversity of Clostridium difficile in Hospitalized Patients in Greece

M. Kachrimanidou, et al.
Journal of Medical Microbiology (Year: N/A)
Summary: In this national-scale study, Dr. Kachrimanidou led efforts to apply whole-genome sequencing and ribotyping to characterize the genomic landscape of C. difficile in Greece. Results highlighted the dominance of ribotype 027 and revealed several emerging strains with unique toxin gene arrangements.

9. Environmental Surveillance for Clostridioides difficile Spores in Healthcare Facilities

M. Kachrimanidou, et al.
Infection Prevention in Practice (Year: N/A)
Summary: This applied research study focused on environmental swabbing and PCR-based detection of C. difficile spores across high-touch hospital surfaces. Findings revealed unexpected hotspots of contamination, underlining the need for updated cleaning protocols and spore-specific disinfectants.

10. Role of Microbial Communities in Antimicrobial Resistance Spread Across Human, Animal, and Environmental Reservoirs

M. Kachrimanidou, et al.
Frontiers in Microbiology (Year: N/A)
Summary: This collaborative review mapped the microbial resistome across sectors. Dr. Kachrimanidou contributed to the discussion on mobile genetic elements, integrons, and plasmid-mediated resistance—particularly in Enterobacteriaceae—arguing for unified surveillance across clinical and agricultural microbiomes.

Conclusion

Dr. Melania Kachrimanidou is a highly qualified candidate for a Best Researcher Award, particularly in the field of clinical microbiology and infectious diseases. Her combination of medical training, PhD research, strong international exposure (especially in the UK), and ongoing academic leadership reflects a well-rounded and committed research career.